La vendita allo scoperto per BeyondSpring dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BeyondSpring. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BeyondSpring (NASDAQ:BYSI) Azioni, Report sulle vendite allo scoperto

BeyondSpring

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

BeyondSpring Inc

Dentalcorp Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DNTL#TSX">DNTL</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.14 by 28.57 percent. This is a 23.08 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $409.40 million which beat the analyst consensus estimate of $404.60 million by 1.19 percent. This is a 9.94 percent increase over sales of $372.40 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

TSX:DNTL

Dentalcorp Holdings Q1 Adj. EPS $0.10 Misses $0.14 Estimate, Sales $409.40M Beat $404.60M Estimate

Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) .

Guidance

Superior Industries Intl  is withdrawing its 2025 fiscal year outlook due to the uncertainties related to the current macroeconomic environment as well as the lost volume from certain customers

Macerich Q1 FFO $0.33 Beats $0.31 Estimate, Sales $249.22M Beat $220.01M Estimate

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) sees Q2 sales of $18.000 million-$20.000 million vs $19.20 million analyst estimate.

HBIO

Harvard Bioscience Sees Q2 Sales $18.000M-$20.000M vs $19.20M Est

Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) affirms FY2025 sales outlook from $84.00 million-$88.00 million to $84.00 million-$88.00 million vs $75.30 million estimate.

Wag Group Affirms FY2025 Sales Guidance of $84.00M-$88.00M Vs $75.30M Est.

Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $5.39 million which missed the analyst consensus estimate of $6.69 million by 19.45 percent. This is a 16.67 percent decrease over sales of $6.47 million the same period last year.

TNGX

Tango Therapeutics Q1 EPS $(0.36) Misses $(0.35) Estimate, Sales $5.39M Miss $6.69M Estimate

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) sees Q2 sales of $292.000 million-$294.000 million vs $275.78 million analyst estimate.

MNDY

Monday.Com Sees Q2 Sales $292.000M-$294.000M vs $275.78M Est

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) raises FY2025 sales outlook from $1.21 billion-$1.22 billion to $1.22 billion-$1.23 billion vs $1.21 billion estimate.

Monday.Com Raises FY2025 Sales Guidance from $1.21B-$1.22B to $1.22B-$1.23B vs $1.21B Est

<ul>
<li>Data at Week 48 demonstrated that treatment with AMX0035 led to sustained stabilization or improvement in multiple outcomes related to disease progression, including pancreatic function, glycemic control, vision, and overall symptom burden</li>
<li>AMX0035 continued to be generally well-tolerated in all participants&nbsp;</li>
<li>Week 48 data and discussions with FDA will inform the design of a Phase 3 trial of AMX0035 in Wolfram syndrome</li>
<li>Amylyx continues to expect cash runway through the end of 2026</li>
</ul>

Biotech

Health Care

General

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharmaceuticals Announced Week 48 Data From The Phase 2 Open-label HELIOS Trial Of AMX0035 In Adults Living With Wolfram Syndrome

Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $15.16 million which missed the analyst consensus estimate of $19.30 million by 21.42 percent. This is a 34.69 percent decrease over sales of $23.22 million the same period last year.

Wag Group Q1 EPS $(0.10) Misses $(0.07) Estimate, Sales $15.16M Miss $19.30M Estimate

Canaccord Genuity analyst Joseph Vafi maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and maintains $32 price target.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Hut 8, Maintains $32 Price Target

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has seen a stratospheric rise since its inception in 2009. Those who identified its potential and invested when it was still in its infancy have witnessed returns that very few assets can compete with.
What happened: Eric Elliott is one such Bitcoin OG who started mining the apex cryptocurrency in 2011.&nbsp;&nbsp;
Elliott, a computer developer, spent around $100 to create a computer geared for Bitcoin mining—the act of using computational power to solve complicated cryptographic problems and earning BTC as a reward.
"When I put it online, I was probably mining one Bitcoin a day," Elliott said during a 2013 interview with CNN Business. "I haven&#8217;t really spent much of the Bitcoins apart from reinvesting them in new hardware."
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How I make money mining bitcoins" width="500" height="281" src="https://www.youtube.com/embed/yFE2FV9ia1s?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Assume Elliott mined 365 BTCs altogether in 2011, gave up mining altogether, and adopted a HODL approach. On Dec. 31, 2011, BTC traded at $4.61 apiece, meaning that his stash would be worth $1,682.75.
Fast forward to May 2025, when the apex cryptocurrency is worth $104,343.23. Had he held on to his stockpile, it would be worth $38.085 million today, representing an eye-popping 6100.76% return in 13.5 years.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45275169/ethereum-stagnant-after-pectra-upgrade-but-analyst-deems-the-overhaul-tailwind-that-could-power-eth-above-2000">Ethereum Flat After Pectra Upgrade, But Analyst Foresees Overhaul &#8216;Tailwind&#8217; That Could Take ETH Above $2,000</a>
While it is clear that Elliott sold the Bitcoin to cover mining costs, he made a candid admission during the interview.&nbsp;
"If you want to make money with Bitcoin, mining is not the way to do it. You&#8217;re better off trading Bitcoin," he said.
Given the significant increase in mining difficulty and expenses, about $137,000 per coin as of the fourth quarter of 2024, Elliott's advice appeared to have some merit.
Price Action:&nbsp; At the time of writing, Bitcoin was exchanging hands at $104,343.23, up 1.80% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45277600/trumps-crypto-policy-like-a-large-buffet-says-anthony-scaramucci-you-have-to-eat-everything-at-the-table">Anthony Scaramucci Compares Trump&#8217;s Crypto Policy To Mar-A-Lago Buffet: &#8216;You Have To Eat Everything At The Table&#8217;</a></li>
</ul>
Photo Courtesy: creativeneko on Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

This Bitcoin OG Mined 1 BTC A Day In 2011—Here's How Much A 365 BTC Stash Would Be Worth Now

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) battery supplier Contemporary Amperex Technologies Co. Ltd., plans to raise over $4 billion through a stock listing on Hong Kong's stock exchange.
What Happened: The Chinese battery giant will aim to raise the figure by selling over 117.9 million shares priced at HK$263 ($33.75) on the Hong Kong stock exchange, Reuters reported on Monday.
The report also suggests that the deal could be raised to $5.3 billion if an offer size adjustment and a Greenshoe option are implemented, which essentially allows the underwriters to sell more shares if there is sufficient demand.
This is the biggest listing on the planet so far this year, the report said and the final price for the listing could be announced on or before May 19. The company says it will use the money raised to develop its Hungary manufacturing facility.
Why It Matters: News of the listing comes in as CATL <a href="https://www.benzinga.com/markets/asia/25/02/43613949/tesla-supplier-catl-eyes-5-billion-hong-kong-listing-amid-us-sanctions-market-revival-report">was previously eyeing a listing</a> in Hong Kong worth over $5 billion amid growing U.S.-China trade tensions.
The China-based EV battery manufacturer had also recently taken the wraps off its new battery, which offers <a href="https://www.benzinga.com/markets/25/04/44894382/tesla-battery-supplier-catl-unveils-new-fast-charging-battery-with-323-mile-range-in-five-minutes">over 323 miles of range</a> on a 5-minute charge.
CATL's clients include companies like Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), as well as Volkswagen AG (OTCPK: VLKAF).
Elsewhere, the Chinese EV industry is making headway into other markets throughout the world, with BYD Co.Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) having laid out plans to construct a <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">factory in Hungary</a> to aid its European strategy. The factory could help BYD produce over 200,000 vehicles annually.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44945220/chinas-geely-announces-it-will-share-battery-safety-patents-safety-lab-with-the-auto-industry">China&#8217;s Geely To Share Battery Safety Patents, Unveils World&#8217;s Largest EV Safety Lab At Shanghai Auto Show</a></li>
</ul>
Image Via Shutterstock

Asia

IPOs

Tech

BYDDF

BYDDY

TSLA

VLKAF

Tesla Battery Supplier CATL Eyes Over $4B In Hong Kong Listing — Could Become 2025's Biggest IPO Yet

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.70 by 57.14 percent. This is a 80.33 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $282.25 million which beat the analyst consensus estimate of $275.78 million by 2.35 percent. This is a 30.12 percent increase over sales of $216.91 million the same period last year.

Monday.Com Q1 Adj. EPS $1.10 Beats $0.70 Estimate, Sales $282.25M Beat $275.78M Estimate

Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) affirms FY2025 sales outlook from $245.00 million-$265.00 million to $245.00 million-$265.00 million vs $256.33 million estimate.

BLDE

Blade Air Mobility Affirms FY2025 Sales Guidance of $245.00M-$265.00M vs $256.33M Est

Lightbridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) reported quarterly losses of $(0.24) per share. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

LTBR

Lightbridge Q1 EPS $(0.24) Down From $(0.21) YoY

Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.53) by 73.58 percent. This is a 22.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $321.60 million which beat the analyst consensus estimate of $300.49 million by 7.03 percent. This is a 1.68 percent increase over sales of $316.30 million the same period last year.

Superior Industries Intl Q1 EPS $(0.92) Misses $(0.53) Estimate, Sales $321.60M Beat $300.49M Estimate

Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) affirms FY2025 GAAP EPS guidance from $2.07-$2.11 to $2.07-$2.11 vs $2.10 analyst estimate..

WTRG

Essential Utilities Affirms FY2025 GAAP EPS Guidance of $2.07-$2.11 vs $2.10 Est

Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $54.31 million which beat the analyst consensus estimate of $49.43 million by 9.86 percent. This is a 5.42 percent increase over sales of $51.51 million the same period last year.

Blade Air Mobility Q1 EPS $(0.04) Beats $(0.11) Estimate, Sales $54.31M Beat $49.43M Estimate

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 150 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $21.77 million which beat the analyst consensus estimate of $19.20 million by 13.41 percent. This is a 11.17 percent decrease over sales of $24.51 million the same period last year.

Harvard Bioscience Q1 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $21.77M Beat $19.20M Estimate

Press Releases

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Financing

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Comments

BeyondSpring

Vendite allo scoperto

BeyondSpring (NASDAQ:BYSI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO